$MLP

Original-Research: MLP SE (von NuWays AG): BUY

NuWays AG reiterated a BUY on MLP SE (DE0006569908) and kept a 12-month target price at EUR 12. It cited Q2 2026 EBIT of EUR 19.1m versus EUR 4.9m a year earlier, driven by higher AuM, performance fees and improved interest income. FY26e EBIT was raised to EUR 116m from EUR 113m, with guidance confirmed but viewed as conservative.

Original reporting
Published Aug 14, 2026, 7:30 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 14, 2026, 8:02 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$MLP
Bullish
medium confidence
Mentioned
$MLP
Relevance
4/10
alphai data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$MLPBullishLow
01

Why it matters

The actionable content is the raised FY26e EBIT estimate and reiterated target price, grounded in Q2 EBIT step-change and a conservative view of H2 guidance versus historical seasonality.

02

Market read

Traders may use the update to gauge sentiment and estimate revisions for MLP, but it is not a new earnings release or regulatory event.

03

What to watch

Execution risk around performance-fee realization and the sustainability of managed non-life premium growth could diverge from the model, especially if market conditions change.

Relevance 4/10Novelty 4/10Timing: pre-market research note dated 14.08.2026 09:00 CET

Background

This is an EQS-distributed analyst research update from NuWays AG on MLP SE, classifying it as BUY and discussing Q2 drivers and FY26e outlook.

Company-level read

Ticker impact

$MLPBullishMedium confidence
Context

NuWays AG reiterates a BUY on MLP SE and raises FY26e EBIT to €116m, citing Q2 EBIT jump and conservative guidance.

Expected impact

Near-term bias to the upside if the market treats the raised FY26e EBIT and PT as incremental, but magnitude likely limited versus an actual results release.

Evidence & confidence

The article provides specific forecast math (FY26e EBIT €116m vs €113m) and a PT €12, yet it is still an analyst research update rather than a new primary disclosure from MLP.

Market effects

Supports sentiment for German wealth management and insurance-linked revenue models via emphasis on recurring revenue and AuM-driven performance fees.

Minor, Germany-focused read-through via ECB rate path assumption supporting interest income into H2.

Limited, primarily affects European financials/wealth managers sentiment rather than global cross-asset drivers.

Counterpoint

The note flags that H2 guidance assumptions look conservative and performance fees are assumed to stop, which could mean upside is capped if performance fees normalize.

Key entities

  • MLP SE

    German wealth management and insurance group; subject of the research update with BUY rating and PT €12.

  • NuWays AG

    Equity research provider issuing the BUY update and forecast changes.

  • Simon Keller

    Named analyst author of the research update.

Related articles

$MLPMed

MAUI LAND & PINEAPPLE CO INC (MLP): Results of Operations and Financial Condition

MAUI LAND & PINEAPPLE CO INC (MLP) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_1000864.htm EXHIBIT 99.1 ex_1000864.htm Exhibit 99.1 Maui Land & Pineapple Company, Inc. Reports Fiscal Second Quarter 2026 Results KAPALUA, Hawai ‘ i / August 14, 2026 (BusinessWire) – Maui Land & Pineapple Company, Inc. (NYSE: MLP) today reported financial results

$BAMedAI 8/10

Pentagon inks deals with Boeing, RTX to boost production of SM-3 components

The Pentagon signed seven-year framework agreements with Boeing and RTX to expand production of Standard Missile-3 components for SM-3 Block IB and Block IIA, including avionics and ejector assemblies Boeing supplies to Raytheon. The deals aim to stabilize supply chains and expand munitions output. Separately, the Missile Defense Agency awarded Raytheon a $745 million contract for Block IIA interceptors.

$BCLIMed

BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update

BrainStorm Cell Therapeutics (OTCQB: BCLI) reported Q2 2026 results for the quarter ended June 30, 2026. It said it is preparing to start the Phase 3b ENDURANCE study of NurOwn in ALS under an FDA-agreed Special Protocol Assessment, planning about 200 patients. Cash was about $0.2M vs $1.03M a year earlier, with Q2 net loss about $3.9M. The company appointed Peter J. Pitts as Executive Chairman and raised about $400k in private placements.

$MARAMed

Crypto Biz: Bitcoin ETFs Rebound as Crypto Miners Extend AI Pivot

A $116 million Coldcard hardware wallet exploit renewed scrutiny of self-custody as US spot Bitcoin ETFs saw about $1 billion in net inflows for the week, according to Bloomberg. Strategy CEO Phong Le said Strategy will resume Bitcoin accumulation later this year; Riot Platforms reported a 20-year $9 billion compute deal with Anthropic. Trump Media plans to revamp its crypto treasury after a $238 million Q2 net loss.